A phase I/II trial for house dust mite rhinitis with a new improved hdm-ASIT+ product.
Latest Information Update: 27 Sep 2022
At a glance
- Drugs House dust mite allergy immunotherapy (Primary)
 - Indications Rhinoconjunctivitis
 - Focus Adverse reactions; Therapeutic Use
 
Most Recent Events
- 01 Feb 2018 New trial record
 - 25 Jan 2018 According to an ASIT biotech media release, this trial is due to be initiated in early 2019.